Form 4: JNJ Executive Kathryn Wengel Executes Stock Option Exercise

Johnson & Johnson EVP Kathryn Wengel exercised 10,000 stock options and subsequently sold the shares on June 11, 2026.

Summary

• Kathryn E. Wengel, EVP, Chief TO and Risk Officer at Johnson & Johnson, exercised 10,000 employee stock options at a strike price of $115.67.
• Following the exercise, the reporting person sold the 10,000 shares at a weighted average price of $241.15.
• The transaction resulted in a net change of zero to the reporting person's direct holdings of common stock, which stands at 114,287.8735 shares post-transaction.
• The sale was executed in multiple trades with prices ranging from $240.14 to $240.19.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard executive compensation activity with no impact on the company's fundamental business operations.

Positives

• The transaction reflects standard executive compensation exercise and liquidation behavior rather than a change in long-term confidence.

Negatives

• The sale of 10,000 shares reduces the direct equity stake held by a key executive.

Risks

• None identified; this is a routine disclosure of executive equity transactions.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that this is a routine Form 4 filing. Executive stock sales following option exercises are common practice for liquidity and tax management and do not typically signal a shift in corporate strategy or outlook.

Comparison to Industry Standards

• The transaction aligns with standard executive equity management practices observed at large-cap pharmaceutical companies like Pfizer, Merck, and Eli Lilly.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine exercise and sale of vested options.

Key Dates

Keywords

Johnson & Johnson, JNJ, Form 4, Insider Trading, Executive Compensation, Stock Options